Complete financial analysis of Jounce Therapeutics, Inc. (JNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jounce Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Singular Genomics Systems, Inc. (OMIC) Income Statement Analysis – Financial Results
- Lipum AB (publ) (LIPUM.ST) Income Statement Analysis – Financial Results
- Sera Prognostics, Inc. (SERA) Income Statement Analysis – Financial Results
- Hu Lane Associate Inc. (6279.TWO) Income Statement Analysis – Financial Results
- Bolsa Mexicana de Valores, S.A.B. de C.V. (BOLSAA.MX) Income Statement Analysis – Financial Results
Jounce Therapeutics, Inc. (JNCE)
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 103.27M | 88.98M | 78.69M | 67.14M | 70.05M | 67.80M | 34.90M | 22.13M | 11.24M |
| General & Administrative | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Other Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Cost & Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.09M | 2.83M | 3.40M | 3.85M | 3.83M | 4.42M | 1.94M | 1.47M | 1.11M |
| EBITDA | -50.16M | -91.06M | -45.12M | 52.82M | -23.50M | -11.99M | -11.76M | -27.06M | -9.41M |
| EBITDA Ratio | -61.16% | -338.41% | -72.37% | 35.72% | -36.05% | -16.73% | -31.61% | 0.00% | 0.00% |
| Operating Income | -52.24M | -91.06M | -45.12M | 52.82M | -31.29M | -19.22M | -14.47M | -30.40M | -16.21M |
| Operating Income Ratio | -63.71% | -338.41% | -72.37% | 35.72% | -48.00% | -26.82% | -38.89% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 3.96M | 2.81M | 763.00K | 1.86M | 5.70M |
| Income Before Tax | -50.78M | -90.86M | -43.83M | 56.87M | -27.33M | -16.41M | -13.70M | -28.53M | -10.52M |
| Income Before Tax Ratio | -61.93% | -337.67% | -70.31% | 38.46% | -41.92% | -22.90% | -36.84% | 0.00% | 0.00% |
| Income Tax Expense | 135.00K | 15.00K | 14.00K | 46.00K | 46.00K | 36.00K | 763.00K | 1.86M | 5.70M |
| Net Income | -50.92M | -90.87M | -43.84M | 56.82M | -27.38M | -16.44M | -13.70M | -28.53M | -10.52M |
| Net Income Ratio | -62.10% | -337.73% | -70.33% | 38.43% | -41.99% | -22.95% | -36.84% | 0.00% | 0.00% |
| EPS | -0.99 | -1.82 | -1.24 | 1.72 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| Weighted Avg Shares Out | 51.68M | 49.93M | 35.43M | 33.08M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
| Weighted Avg Shares Out (Dil) | 51.68M | 49.93M | 35.43M | 34.29M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts –
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation...
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q2 2021 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q2 2021 Results - Earnings Call Transcript
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial results...
Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies.
Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Officer will participate...
Why Jounce Therapeutics Bounced Higher Today
The company gets a regulatory nod that will put $25 million in its pocket.
Stop Checking Your Portfolio: How to Invest for the Long Term During a Market Crash
Crashes aren't very frightening if you're mentally and financially prepared.
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports